Nanomedicine: Application of nanotechnology in medicine. Opportunities in neuropsychiatry;Nanomedicina: A nanotechnológia alkalmazása az orvostudományban. Lehetőségek a neuropszichiátria területén

Neuropsychopharmacologia Hungarica

Volumn 13, Issue 1, 2011, Pages 15-24

  János, Szebeni ^a  

^a UNIVERSITY OF MISKOLC   (Hungary)

Author keywords

Blood brain barrier; Liposomes; Nanocarriers; Nanotherapy; Neuropsychopharmacons; Targeted pharmacotherapy

Indexed keywords

APTAMER; CARBON NANOTUBE; DENDRIMER; DOXORUBICIN; LIPOSOME; POLYMER;

BLOOD BRAIN BARRIER; DRUG TARGETING; HUMAN; MICELLE; NANOMEDICINE; NANOTECHNOLOGY; NEUROPSYCHIATRY; PSYCHOPHARMACOTHERAPY; REVIEW;

EID: 79955812889     PISSN: 14198711     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (11)

1. Alyaudtin, R. N., Reichel, A., Löbenberg, R., Ramge, P., Kreuter, J., and Begley, D. (2001). Interaction of poly(butylcyanoacrylate) nanoparticles with the blood-brain barrier in vivo and in vitro. Journal Drug Targeting 9, 209-221.
2. Barenholz, Y. (2006). Amphipathic weak base loading into preformed liposomes having a transmembrane ammonium ion gradient: From the bench to approved DOXIL, In "Liposome Technology Vol 2" (G. Gregoriadis, ed.), 1-26. Informa Healthcare, New York, NY.
3. Cerletti, A., Fricker, G., Eberle, A. N., and Huwyler, J. (2000). Endocytosis and transcytosis of an immunoliposome-based brain drug delivery system. J Drug Target 8, 435-46.
4. Chertoka, B., Davida, A. E., and Yanga, V.C. (2010). Polyethyleneimine-modified iron oxide nanoparticles for brain tumor drug delivery using magnetic targeting and intra-carotid administration. Biomaterials 31, 6317-6324.
5. Dhanikula, R. S., Argaw, A., Bouchard, J. F., and Hildgen, P. (2008). Methotrexate loaded polyether-copolyester dendrimers for the treatment of gliomas: Enhanced efficacy and intratumoral transport capability. Mol. Pharmaceutics 5, 105-116.
6. Gabizon, A., Catane, R., Uziely, B., Kaufman, B., Safra, T., Cohen, R., Martin, F., Huang, A., and Barenholz, Y. (1994). Prolonged circulation time and enhanced accumulation in malignant exudates of doxorubicin encapsulated in polyethylene-glycol coated liposomes. Cancer Res 54, 987-992.
7. Gabizon, A., Shmeeda, H., and Barenholz, Y. (2003). Pharmacokinetics of pegylated liposomal Doxorubicin: Review of animal and human studies. Clin. Pharmacokinetics 42, 419-436.
8. Miklya, I. (2010). [The feasibility of synthetic enhancer substances for preventive nanotherapy]. Neuropsychopharmacologia Hungarica 12, 395-403.
9. Pardridge, W. M. (2005). Tyrosine hydroxylase replacement in experimental Parkinson's disease with transvascular gene therapy. NeuroRx 2, 129-138.
10. Wagner, V., Dullaart, A., Bock, A.-K., and Zweck, A. (2006). The emerging nanomedicine landscape. Nature Biotechnol. 24, pp. 1211-17.
11. Wang, Z. H., Wang, Z. Y., Sun, C. S., Wang, C. Y., Jiang, T. Y., and Wang, S. L. (2010). Trimethylated chitosan-conjugated PLGA nanoparticles for the delivery of drugs to the brain. Biomaterials 31, pp. 908-915.